Home>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA Alkylator/Crosslinker>>Temozolomide


Catalog No.GC13667

Temozolomide Chemical Structure

An oral DNA alkylating agent used to treat some brain cancers

Size Price Stock Qty
10mM (in 1mL DMSO)
In stock
In stock
In stock
In stock
In stock
In stock
In stock

Customer Reviews

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:


Cell experiment [1]:

Cell lines

SK-LMS-1 leiomyosarcoma (MGMT-/p53+), Ewing sarcoma A-673 and GIST-T1 (both lines with MGMT+/p53- phenotype), and glioblastoma T98G (MGMT+/p53+)

Preparation method

The solubility of this compound in DMSO is >6.6mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

62.5, 125, 250 and 500 μM; 72 h


In SK-LMS-1 cells, Temozolomide inhibited proliferative activity of SK-LMS-1 cells. A-673 cells was most sensitive to temozolomide, the effect was time- and dose-dependent. Preincubation of Ewing sarcoma cells with O6-benzylguanine potentiated the cytotoxic effect of the alkylating agent and reduced viability of tumor cells. GIST-T1 cells were insensitive to temozolomide.

Animal experiment [2]:

Animal models

PARP1 wild‐type (WT) and PARP1 knock‐out (KO) mice

Dosage form

68 mg/kg; once daily for 5 days; orally administrated


In PARP1 WT mice, temozolomide significantly lowered concentrations of NAD+ in the liver when compared with the control group (by 22%, p = 0.02). In the livers of PARP1 KO mice, there was also a statistically significant reduction in NAD+ in the temozolomide‐only group when compared with the control (by 22%, p = 0.03).

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1] Khusnutdinov RR1, Boichuk SV2. Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide. Bull Exp Biol Med. 2017 Jul 18.

[2]. Almeida GS1, Bawn CM1, Galler M1, et al. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR Biomed. 2017 May 22.


Temozolomide (NSC 362856; CCRG 81045) is an oral DNA alkylating agent used to treat some brain cancers.
Temozolomide (TZM) is a methylating agent that crosses the blood-brain barrier and is indicated for malignant gliomas and metastatic melanomas. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system (MR)[1]. Determination of the IC50 for Temozolomide (TZM) in different cell lines gave values ranging from 14.1 to 234.6 μM that fell into two clearly differentiated groups: cell lines with low IC50 values (<50 μM), which include A172 (14.1±1.1 μM) and LN229 cells (14.5±1.1 μM), and those with high IC50 values (>100 μM), which include SF268 (147.2±2.1 μM) and SK-N-SH cells (234.6±2.3 μM)[2].
Temozolomide (TZM), as a single agent, does not significantly increase mdian survival time (MST) with respect to control. Noteworthy, intracranial injection of NU1025, immediately before the administration of 100 or 200 mg/kg Temozolomide, significantly increases lifespans with respect to controls or to groups treated with Temozolomide only. When Temozolomide is fractionated, the increase in lifespan (ILS) obtained with this schedule is higher than that observed when NU1025 is combined with a single injection of Temozolomide (statistical comparison of survival curves: NU1025 intracranially+Temozolomide 100 mg/kg×2 vs NU1025+Temozolomide 200 mg/kg; P=0.023)[1].
[1]. Tentori L, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002 Mar 15;99(6):2241-4.
[2]. Perazzoli G, et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One. 2015 Oct 8;10(10):e0140131.

Chemical Properties

Cas No. 85622-93-1 SDF
Synonyms N/A
Chemical Name 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
Canonical SMILES CN1C(=O)N2C=NC(=C2N=N1)C(=O)N
Formula C6H6N6O2 M.Wt 194.15
Solubility ≥ 29.61mg/mL in DMSO Storage Store at -20°C, protect from light, stored under nitrogen
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

  • Molarity Calculator

  • Dilution Calculator

**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).



Review for Temozolomide

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
4 Star
3 Star
2 Star
1 Star
Review for Temozolomide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.